The Physiology and Molecular Underpinnings of the Effects of Bariatric Surgery on Obesity and Diabetes

2017 ◽  
Vol 79 (1) ◽  
pp. 313-334 ◽  
Author(s):  
Simon S. Evers ◽  
Darleen A. Sandoval ◽  
Randy J. Seeley
Keyword(s):  
Bariatric Surgery ◽  
Obesity And Diabetes

scholarly journals Preoperative Cardiac Diagnostics in Bariatric Patients with Diabetes and Perioperative Morbidity: Results of a Cohort of 258 Patients

2021 ◽  
Author(s):  
Benjamin Stillhard ◽  
B. T. Truc Ngo ◽  
Ralph Peterli ◽  
Thomas Peters ◽  
Romano Schneider ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Myocardial Perfusion ◽  
Cardiac Catheterization ◽  
Myocardial Perfusion Scintigraphy ◽  
Perfusion Scintigraphy ◽  
Perioperative Morbidity ◽  
Obesity And Diabetes ◽  
Patients With Diabetes ◽  
Cardiac Assessment ◽  
Bariatric Patients

Abstract Purpose The combination of obesity and diabetes mellitus are well-known risk factors for cardiovascular complications and perioperative morbidity in metabolic surgery. The aim of this study was to evaluate effectivity and reliability of the cardiac assessment in patients with diabetes prior to bariatric surgery. Setting Private, university-affiliated teaching hospital, Switzerland Material and Methods Retrospective analysis of prospectively collected data on results and consequences of cardiac assessments in 258 patients with obesity and diabetes scheduled for primary bariatric surgery at our institution between January 2010 and December 2018. Results Out of 258 patients, 246 (95.3%) received cardiac diagnostics: 173 (67.1%) underwent stress-rest myocardial perfusion scintigraphy (MPS), 15 (5.8%) patients had other cardiac imaging including cardiac catheterization, 58 (22.5%) patients had echocardiography and/or stress electrocardiography, and 12 (4.7%) patients received no cardiac evaluation. Subsequently, cardiac catheterization was performed in 28 patients (10.9%), and coronary heart disease was detected and treated in 15 subjects (5.8%). Of these 15 individuals, 5 (33.3%) patients had diffuse vascular sclerosis, 8 (53.3%) patients underwent coronary angioplasty and stenting, and 2 (13.3%) patients coronary artery bypass surgery. Bariatric surgery was performed without perioperative cardiovascular events in all 258 patients. Conclusion Our data suggest that a detailed cardiac assessment is mandatory in bariatric patients with diabetes to identify those with yet unknown cardiovascular disease before performing bariatric surgery. We recommend carrying out myocardial perfusion scintigraphy as a reliable diagnostic tool in this vulnerable population. If not viable, stress echocardiography should be performed as a minimum.

scholarly journals Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study

2021 ◽  
Author(s):  
Kajsa Sjöholm ◽  
Lena MS Carlsson ◽  
Per-Arne Svensson ◽  
Johanna C. Andersson-Assarsson ◽  
Felipe Kristensson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Cancer Risk ◽  
Cancer Incidence ◽  
Diabetes Remission ◽  
Obesity And Diabetes ◽  
Obese Subjects

<b>OBJECTIVE</b> <p>Obesity and type 2 diabetes are associated with serious, adverse health effects, including cancer. Although bariatric surgery has been shown to reduce cancer risk in patients with obesity, the effect of bariatric surgery on cancer risk in patients with obesity and diabetes is less studied. We therefore examined the long-term incidence of cancer after bariatric surgery and usual care in patients with obesity and diabetes in the matched prospective Swedish Obese Subjects (SOS) study. </p> <p><b>RESEARCH DESIGN AND METHODS</b></p> <p>The SOS study examines long-term outcomes following bariatric surgery or usual care. The current analysis includes 701 patients with obesity and type 2 diabetes at baseline, 393 of which underwent bariatric surgery, and 308 who received conventional obesity treatment. Information on cancer events was obtained from the Swedish National Cancer Register. Median follow-up time was 21.3 years (interquartile range 17.6-24.8 years, maximum 30.7 years). </p> <p><b>RESULTS</b></p> <p>During follow-up, the incidence rate for first-time cancer was 9.1 per 1000-person-years (95% CI, 7.2-11.5) in patients with obesity and diabetes treated with bariatric surgery and 14.1 per 1000-person-years (95% CI, 11.2-17.7) in patients treated with usual obesity care (HRadj=0.63; 95% CI 0.44-0.89, p=0.008). Moreover, surgery was associated with reduced cancer incidence in women (HRadj=0.58; 0.38-0.90, p=0.016), although the sex-treatment interaction was non-significant (p=0.630). In addition, diabetes remission at the 10-year follow-up was associated with reduced cancer incidence (HRadj=0.40; 95% CI 0.22-0.74, p=0.003).</p> <p><b>CONCLUSIONS</b></p> <p>These results suggest that bariatric surgery prevents cancer in patients with obesity and diabetes, and that durable diabetes remission is associated with reduced cancer risk. </p>

scholarly journals Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions

2020 ◽  
Vol 13 ◽  
pp. 117955142090584 ◽  
Author(s):  
Annie Hasib
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Hormone Receptors ◽  
Gut Hormones ◽  
Metabolic Effects ◽  
Therapeutic Approaches ◽  
Obesity And Diabetes ◽  
Gut Hormone ◽  
Prevalence Of Obesity

The ever-increasing prevalence of obesity and Type 2 diabetes has necessitated the development of newer and more effective approaches for achieving efficient glycemic control and weight loss. Conventional treatment methods often result in weight gain, further deteriorating the already impaired metabolic control in people with obesity/Type 2 diabetes. Alleviation of obesity and diabetes achieved after bariatric surgeries highlight the therapeutic importance of gut-brain axis and entails development of more patient-friendly approaches replicating the positive metabolic effects of bariatric surgery. Given the potential involvement of several gut hormones in the success of bariatric surgery, the therapeutic importance of synergistic interaction between these hormones for improved metabolism cannot be ignored. Many unimolecular multiagonist peptides are in preclinical and clinical trials as they maximize the combinatorial metabolic efficacy by concurrent activation of multiple gut hormone receptors. This review summarizes the ongoing developments of multiagonist peptides as novel therapeutic approaches against obesity-diabetes.

scholarly journals Diabetes and Obesity

2021 ◽  
Vol 6 (4) ◽  
pp. 1-1
Author(s):  
Daphne Owens ◽  
◽  
Gerald H Tomkin
Keyword(s):  
Myocardial Infarction ◽  
Insulin Resistance ◽  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Bariatric Surgery ◽  
Blood Sugar ◽  
Early Treatment ◽  
Obesity And Diabetes ◽  
Premature Myocardial Infarction ◽  
Diabetes And Obesity

Obesity and Diabetes are leading causes of cardiovascular disease and mortality. They are closely linked because of insulin resistance. Hypertension and dyslipidaemia together with poor exercise drive atherosclerosis. Early treatment of blood sugar, dyslipidaemia and hypertension reverse the atherosclerosis process. Bariatric surgery and low calorie diets have in recent years been shown to reverse or improve blood sugars lipids and blood pressure. The risk of premature myocardial infarction and death should no longer be the desired outcome.

scholarly journals Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study

2021 ◽  
Author(s):  
Kajsa Sjöholm ◽  
Lena MS Carlsson ◽  
Per-Arne Svensson ◽  
Johanna C. Andersson-Assarsson ◽  
Felipe Kristensson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Cancer Risk ◽  
Cancer Incidence ◽  
Diabetes Remission ◽  
Obesity And Diabetes ◽  
Obese Subjects

<b>OBJECTIVE</b> <p>Obesity and type 2 diabetes are associated with serious, adverse health effects, including cancer. Although bariatric surgery has been shown to reduce cancer risk in patients with obesity, the effect of bariatric surgery on cancer risk in patients with obesity and diabetes is less studied. We therefore examined the long-term incidence of cancer after bariatric surgery and usual care in patients with obesity and diabetes in the matched prospective Swedish Obese Subjects (SOS) study. </p> <p><b>RESEARCH DESIGN AND METHODS</b></p> <p>The SOS study examines long-term outcomes following bariatric surgery or usual care. The current analysis includes 701 patients with obesity and type 2 diabetes at baseline, 393 of which underwent bariatric surgery, and 308 who received conventional obesity treatment. Information on cancer events was obtained from the Swedish National Cancer Register. Median follow-up time was 21.3 years (interquartile range 17.6-24.8 years, maximum 30.7 years). </p> <p><b>RESULTS</b></p> <p>During follow-up, the incidence rate for first-time cancer was 9.1 per 1000-person-years (95% CI, 7.2-11.5) in patients with obesity and diabetes treated with bariatric surgery and 14.1 per 1000-person-years (95% CI, 11.2-17.7) in patients treated with usual obesity care (HRadj=0.63; 95% CI 0.44-0.89, p=0.008). Moreover, surgery was associated with reduced cancer incidence in women (HRadj=0.58; 0.38-0.90, p=0.016), although the sex-treatment interaction was non-significant (p=0.630). In addition, diabetes remission at the 10-year follow-up was associated with reduced cancer incidence (HRadj=0.40; 95% CI 0.22-0.74, p=0.003).</p> <p><b>CONCLUSIONS</b></p> <p>These results suggest that bariatric surgery prevents cancer in patients with obesity and diabetes, and that durable diabetes remission is associated with reduced cancer risk. </p>

scholarly journals Treatment of obesity and diabetes with bariatric surgery

2013 ◽  
Vol 1 (1) ◽  
pp. 1 ◽  
Author(s):  
Kevin A Whitlock ◽  
Richdeep S Gill ◽  
Noah Switzers ◽  
Daniel W Birch ◽  
Shahzeer Karmali
Keyword(s):  
Bariatric Surgery ◽  
Obesity And Diabetes ◽  
Treatment Of Obesity

scholarly journals The relationship between specialized pro-resolving lipid mediators, morbid obesity and weight loss after bariatric surgery

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Fabian Schulte ◽  
Abdul Aziz Asbeutah ◽  
Peter N. Benotti ◽  
G. Craig Wood ◽  
Christopher Still ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Morbid Obesity ◽  
Weight Loss ◽  
White Blood Cells ◽  
Diabetes Remission ◽  
Lipid Mediators ◽  
Morbidly Obese ◽  
Post Surgery ◽  
Obesity And Diabetes ◽  
Obese Subjects

AbstractObesity and diabetes are associated with chronic inflammation. Specialized pro-resolving lipid mediators (SPMs)—resolvins (Rv), protectins (PD) and maresins (MaR)—actively resolve inflammation. Bariatric surgery achieves remission of diabetes, but mechanisms are unclear. We measured SPMs and proinflammatory eicosanoid levels using liquid chromatography-tandem mass spectrometry in 29 morbidly obese subjects (13 with diabetes) and 15 nondiabetic, mildly obese subjects. Compared to the mildly obese, the morbidly obese had higher levels of SPMs—RvD3, RvD4 and PD1—and white blood cells (WBC) and platelets. Post-surgery, SPM and platelet levels decreased in morbidly obese nondiabetic subjects but not in diabetic subjects, suggesting continued inflammation. Despite similar weight reductions 1 year after surgery (44.6% vs. 46.6%), 8 diabetes remitters had significant reductions in WBC and platelet counts whereas five non-remitters did not. Remitters had a 58.2% decrease (p = 0.03) in 14-HDHA, a maresin pathway marker; non-remitters had an 875.7% increase in 14-HDHA but a 36.9% decrease in MaR1 to a median of 0. In conclusion, higher levels of RvD3, PD1 and their pathway marker, 17-HDHA, are markers of leukocyte activation and inflammation in morbid obesity and diabetes and diminish with weight loss in nondiabetic but not diabetic subjects, possibly representing sustained inflammation in the latter. Lack of diabetes remission after surgically-induced weight loss may be associated with reduced ability to produce MaR1 and sustained inflammation.

scholarly journals The Clinical Effectiveness and Cost Effectiveness of Bariatric Metabolic Surgery for Obese with Poorly Controlled Type 2 Diabetes Patients In Malaysia - A Study Protocol

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1634-1634
Author(s):  
Jo Ann Galvan ◽  
Karuthan Chinna ◽  
Rusli Nordin ◽  
Nik Kosai Mahmood ◽  
Chin Kin Fah ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Cost Effectiveness ◽  
Study Protocol ◽  
Diabetes Care ◽  
Clinical Effectiveness ◽  
Term Effect ◽  
Short Term ◽  
Post Surgery ◽  
Obesity And Diabetes

Abstract Objectives Bariatric Surgery is a major breakthrough in diabetes care. Complete remission is attainable in a great percentage of patients. However, there is slow progress in this procedure in Malaysia. With the overwhelming rate of obesity and diabetes in the country, the potential advantage of this treatment modality is underestimated. Conventional diabetes care only controls 22% of the diabetics and healthcare expenditure has ballooned due to complications costs amounting to at least RM 2 billion in a year eating up 10% of the government's budget on healthcare. Furthermore, this burden will increase in the next decades as diabetes is predicted to increase by 69% by 2030. While this procedure is beneficial, it is an expensive intervention with risks of complications. This raises the question of whether bariatric surgery is cost-effective in the context of this country? Evidence must be available to decision-makers weighing the risk-benefit ratio of the procedure. This study aims to assess the clinical effectiveness and cost-effectiveness of bariatric surgery in managing obesity among the Malaysian population. It will specifically investigate the short term and long-term effects of the procedure investigating anthropometric and metabolic disease blood indicator changes while assessing direct, indirect costs, QALYs gained and complications associated with the procedure. Methods We will review charts of all patients who have undergone bariatric surgery procedures from 2014 to 2016 in HUKM, Department of Surgery and in Andrea Bariatric Surgery Clinic. We will look at their weight, BMI, and some blood parameter results before and after surgery one-year post-surgery for the short-term effect and 3–5 years post-surgery for the long-term effect. We will also assess the mortality risks and complications of the procedures. Study Population: All patients who underwent Bariatric Surgery procedures from 2014–206 in HUKM and in Andrea Bariatric Surgery ClinicStudy Site/Location: HUKM, Department of Surgery & Andrea Bariatric Surgery Clinic Results N/A - Study Protocol Conclusions The result of this study can contribute to the decision making of patients, doctors, and Health Insurance Companies in Malaysia Funding Sources Center for Research Management, Taylor's University.

Sign in / Sign up

Export Citation Format

Share Document